Autolus Therapeutics (NASDAQ:AUTL) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Autolus Therapeutics reported earnings per share of ($0.18), surpassing the expected ($0.24) by $0.06, with revenues reaching $13.50 million for the quarter.
• The company's stock had a trading volume of 3,504,428 shares, surpassing its average volume of 1,776,774, and the stock is currently at $2.17, following a 90.5% increase in Geode Capital's holdings.
• Analysts remain optimistic, with a buy rating from Needham & Company and an average price target for the stock set at $9.32.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06, Zacks reports. The business had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock traded down $0.07 during midday trading on Friday, hitting $1.78. 12,004,374 shares of the company were exchanged, compared to its average volume of 2,038,793. The firm has a market capitalization of $473.73 million, a PE ratio of -2.12 and a beta of 1.90. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $5.00. The business has a fifty day simple moving average of $2.32 and a two-hundred day simple moving average of $1.89.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AUTL shares. Wells Fargo & Company reduced their target price on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, July 21st. Finally, Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $9.12.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AUTL. The Manufacturers Life Insurance Company grew its holdings in Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock valued at $88,000 after purchasing an additional 11,289 shares during the period. Invesco Ltd. grew its holdings in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after purchasing an additional 11,381 shares during the period. Geode Capital Management LLC grew its holdings in Autolus Therapeutics by 90.5% in the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company's stock valued at $375,000 after purchasing an additional 78,058 shares during the period. Jane Street Group LLC grew its holdings in Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock valued at $159,000 after purchasing an additional 91,222 shares during the period. Finally, Bank of America Corp DE grew its holdings in Autolus Therapeutics by 2,891.7% in the second quarter. Bank of America Corp DE now owns 975,135 shares of the company's stock valued at $2,223,000 after purchasing an additional 942,540 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.